What AI agents think about this news
The panelists generally agreed that SCHA has a significant liquidity advantage over ISCB due to its larger asset base, but the performance gap is primarily due to index construction and sector exposure, not persistent stock-picking skill. The key risk is that SCHA's tech-heavy exposure could underperform in a rising-rate or growth-rotation environment, while ISCB's defensive tilt could smooth drawdowns but brings policy/regulatory exposure and tracking error risks in stress markets.
Risk: SCHA's tech-heavy exposure underperforming in a rising-rate or growth-rotation environment
Opportunity: ISCB's defensive tilt smoothing drawdowns
Key Points
Both SCHA and ISCB charge a low 0.04% expense ratio but differ sharply in assets under management and trading volume
SCHA delivered a higher 1-year total return, while ISCB has a slightly smaller historical drawdown and a marginally higher dividend yield
ISCB places more emphasis on Healthcare and Industrials, whereas SCHA leans into Technology exposure
- 10 stocks we like better than iShares Trust - iShares Morningstar Small-Cap ETF ›
Schwab U.S. Small-Cap ETF (NYSEMKT:SCHA) and iShares Morningstar Small-Cap ETF (NYSEMKT:ISCB) both offer broad small-cap U.S. equity exposure at a 0.04% expense ratio, but SCHA is much larger and more liquid, while ISCB offers a slightly higher yield and a modest tilt toward Healthcare and Industrials.
For investors comparing SCHA and ISCB, both funds aim to capture the performance of U.S. small-cap stocks, yet they differ in scale, sector allocation, and recent returns. This analysis explores the key differences in cost, performance, risk, and portfolio makeup to help you decide which may fit your portfolio better.
Snapshot (cost & size)
| Metric | SCHA | ISCB | |---|---|---| | Issuer | Schwab | IShares | | Expense ratio | 0.04% | 0.04% | | 1-yr return (as of 2026-04-22) | 47.1% | 38.4% | | Dividend yield | 1.1% | 1.3% | | Beta | 1.10 | 1.08 | | AUM | $22.0 billion | $268.5 million |
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months.
Both ETFs are equally affordable on fees, but ISCB offers a marginally higher dividend yield. SCHA’s much larger size and higher trading volume may appeal to those prioritizing liquidity or institutional scale.
Performance & risk comparison
| Metric | SCHA | ISCB | |---|---|---| | Max drawdown (5 y) | -30.78% | -29.94% | | Growth of $1,000 over 5 years | $1,346 | $1,305 |
What's inside
ISCB tracks a broad mix of U.S. small-caps, with notable allocations to Industrials (18%), Financial Services (16%), and Healthcare (14%) as of its most recent report. The fund holds 1,554 stocks, with its largest positions in Lumentum Holdings Inc (NASDAQ:LITE), Revolution Medicines Inc (NASDAQ:RVMD), and Albemarle Corp (NYSE:ALB), each representing a small fraction of assets. With a fund age of nearly 22 years, ISCB has established a long track record.
By contrast, SCHA tilts more toward Technology (18%), alongside significant weights in Financial Services and Industrials (each 16%). Its top holdings include Sandisk Corp (NASDAQ:SNDK), Lumentum Holdings Inc (NASDAQ:LITE), and Revolution Medicines Inc (NASDAQ:RVMD). SCHA’s asset count is larger, with 1,729 holdings, suggesting slightly broader diversification within the small-cap space.
For more guidance on ETF investing, check out the full guide at this link.
What this means for investors
When two funds track the same corner of the market at the same price, the decision usually comes down to conviction on the vehicle, not the strategy. Five years out, the gap between these two is $41 on a $1,000 investment — close enough that neither fund has proven a structural edge. What small-caps offer at a portfolio level is diversification away from mega-cap concentration, which has dominated large-cap indices for years, and a longer-run historical return premium that tends to materialize over decade-plus horizons, not quarters. The one meaningful difference is sector tilt: SCHA leans harder into Technology, ISCB into Healthcare — and in a significant drawdown, those behave differently. If you already have heavy Tech exposure elsewhere, ISCB's tilt offers a bit more balance. The more useful question either way is whether a 30% drop feels like a threat or an opportunity — investors who can buy into that kind of volatility rather than sell out of it will get considerably more out of whichever fund they choose.
Should you buy stock in iShares Trust - iShares Morningstar Small-Cap ETF right now?
Before you buy stock in iShares Trust - iShares Morningstar Small-Cap ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and iShares Trust - iShares Morningstar Small-Cap ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $500,572! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,223,900!
Now, it’s worth noting Stock Advisor’s total average return is 967% — a market-crushing outperformance compared to 199% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of April 24, 2026. *
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Lumentum. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
"The AUM disparity between SCHA and ISCB is not just a vanity metric; it represents a meaningful difference in execution costs and liquidity risk during periods of high market volatility."
The article frames this as a simple choice between liquidity and sector tilts, but it misses a critical structural risk: the divergence in index construction. SCHA tracks the Dow Jones U.S. Small-Cap Total Stock Market Index, while ISCB follows the Morningstar US Small Cap Index. These methodologies define 'small-cap' differently, leading to varying levels of exposure to micro-cap volatility and profitability filters. While the 0.04% expense ratio is attractive, investors should be wary of the 'liquidity trap' in ISCB; with only $268 million in AUM, it faces higher bid-ask spreads and potential creation/redemption inefficiencies during market stress compared to the $22 billion behemoth that is SCHA.
If you are a long-term passive holder, the AUM difference is irrelevant because the underlying basket of stocks—not the ETF's trading volume—drives your long-term realized returns.
"SCHA's massive liquidity edge and proven outperformance make it the default small-cap ETF choice, with ISCB suitable only for precise sector bets."
SCHA dominates ISCB on liquidity ($22B AUM and high volume vs. $268M), recent performance (47.1% 1-yr total return vs. 38.4%), and diversification (1,729 holdings vs. 1,554), making it far superior for most investors despite identical 0.04% fees. Article glosses over ISCB's closure risk in volatile markets and potential wide bid-ask spreads; SCHA's Tech tilt (18%) fueled outperformance amid AI hype, but small-caps broadly lag mega-caps (Russell 2000 trails S&P 500 over 10 years) due to higher debt burdens and rate sensitivity. Note: Article cites outdated holdings like delisted SanDisk (SNDK) and future dates (2026), undermining credibility.
If rates stay elevated or a recession hits, small-caps crater regardless, but ISCB's lower beta (1.08 vs. 1.10) and Healthcare/Industrials tilt could limit drawdowns better than SCHA's Tech exposure.
"SCHA's liquidity and recent outperformance matter more than sector tilt, but both are bets on small-cap cyclicality that could reverse sharply in a downturn."
This article frames a false equivalence. Yes, both charge 0.04%, but SCHA's $22B AUM versus ISCB's $268.5M creates a massive liquidity moat—tighter spreads, better execution, lower slippage on entry/exit. The 1-year return gap (47.1% vs 38.4%) is 8.7 percentage points; over 5 years SCHA compounds to $1,346 vs $1,305 on $1K. That's not 'close enough'—it's 3.1% outperformance, which at small-cap scale suggests either better index tracking or genuine alpha. The article treats sector tilt as the main differentiator, but ignores that SCHA's tech overweight has been a structural tailwind since 2023. The real risk: if small-cap mean reversion hits hard, SCHA's tech concentration becomes a liability, not an asset.
SCHA's outperformance could be pure timing—tech's dominance is cyclical, not permanent. If value and industrials rotate back in, ISCB's healthcare/industrials tilt becomes the winning bet, and the 8.7% gap reverses.
"Regime shifts and macro factors will be decisive; ISCB’s defensive tilt may prove more durable over full market cycles even if SCHA posts stronger 12-month returns."
The obvious read is that SCHA wins on liquidity and a tech tilt, while ISCB offers modest yield and a healthcare/industrials tilt. But the strongest counterpoint is regime risk: a tech-heavy small-cap bias can crater in a rising-rate/growth-rotation environment, so SCHA's edge may be ephemeral. ISCB’s defensive tilt could smooth drawdowns, but it brings policy/regulatory exposure and, crucially, a much smaller asset base that can worsen tracking error and liquidity in stress. The article glosses over how durable 1-year outperformance is and underestimates the macro sensitivity of these tilts; longer cycles, not quarterly returns, decide winners.
ISCB’s smaller size could magnify tracking error and bid-ask spreads in downturns, so its yield and defensive tilt may not translate into real-world resilience. A tech rally could also render ISCB the laggard in the next cycle.
"The performance gap between SCHA and ISCB is driven by structural index methodology differences rather than ETF management alpha."
Claude, you’re conflating tracking error with alpha. That 8.7% performance gap isn't 'genuine alpha'—it's a direct byproduct of the Dow Jones index’s inclusion of micro-cap growth stocks that the Morningstar index filters out. SCHA is essentially a momentum play on small-cap tech. If you want true small-cap exposure, you're buying the 'wrong' index with SCHA. The liquidity moat is real, but let's stop pretending the return differential is anything other than a different beta profile.
"ISCB's profitability filter offers resilient quality exposure versus SCHA's zombie micro-caps in a higher-rate regime."
Gemini, SCHA's micro-cap inclusion loads up on unprofitable 'zombies' that thrived in low rates but face extinction now—ISCB's Morningstar profitability screen (requiring positive earnings) delivers quality tilt nobody's flagged, echoing Fama-French factors. Amid Fed's balance sheet runoff, this could sustain outperformance as weaklings delist, flipping your 'wrong index' critique.
"ISCB's profitability screen is a real structural difference, but 'zombie' exposure in SCHA remains unquantified—we need holding-level data to validate the quality thesis."
Grok's profitability screen argument is testable but incomplete. ISCB's Morningstar filter does exclude unprofitable micro-caps, but SCHA's 1,729 holdings still include profitable small-caps—the 'zombie' framing overstates the difference. More critical: neither panelist quantified how many SCHA holdings are actually unprofitable or near-delisting. Without that data, we're debating index philosophy, not risk. The real question: does ISCB's quality tilt persist through a recession, or does it just lag less spectacularly? That's the durable edge.
"The 1-year gap is more beta- and construction-driven than durable alpha; in a regime shift or recession, SCHA's tech-heavy small-caps could underperform ISCB's quality tilt, and liquidity stress could erode the edge."
Claude, the 1-year gap you highlight is likely heavily driven by index construction and sector exposure, not persistent stock-picking skill. If rates stay high or recession hits, SCHA's tech-heavy small-caps could underperform ISCB's quality tilt and more defensively positioned holdings. The liquidity moat matters, but an stress-market unwind could widen bid-ask and force unfavorable redemptions, eroding the supposed durability of that 8.7-point edge.
Panel Verdict
No ConsensusThe panelists generally agreed that SCHA has a significant liquidity advantage over ISCB due to its larger asset base, but the performance gap is primarily due to index construction and sector exposure, not persistent stock-picking skill. The key risk is that SCHA's tech-heavy exposure could underperform in a rising-rate or growth-rotation environment, while ISCB's defensive tilt could smooth drawdowns but brings policy/regulatory exposure and tracking error risks in stress markets.
ISCB's defensive tilt smoothing drawdowns
SCHA's tech-heavy exposure underperforming in a rising-rate or growth-rotation environment